Introduction
Benign childhood epilepsy with centrotemporal spikes (BECTS) or Rolandic epilepsy (RE) represents 15-25% of all childhood epilepsy cases and is characterized by brief, simple, partial orofacial motor or sensory seizures during sleep or upon awakening with or without secondary generalization. BECTS is an age-related disease that typically affects children between the ages of 3 and 13 years, peaks between 8 and 10 years and spontaneously remits before the age of 16.
1 Some studies have not recommended treatment due to the benign course and good prognosis of BECTS. 2 However, the frequently recurring seizures, neuropsychological dysfunctions and behavioral abnormalities encountered in children with BECTS are factors that favor prophylaxis with antiepileptic drugs (AEDs). [3] [4] [5] [6] When treatment is planned, priority should be given to monotherapies with agents that have established antiepileptic effects and whose adverse effects are clearly understood. 7 Levetiracetam (LEV) has recently been considered as the initial monotherapy for typical BECTS. 8 The favorable pharmacokinetics and good tolerability of this drug make it an ideal option for pediatric epilepsy. 9 However, the ILAE guidelines recommend monotherapy with valproic acid (VPA) based on level C evidence. 10 One major issue against AED therapy in this population is the potential for side effects. Weight gain is a well-known side effect of VPA, occurs in 40% of children and is the primary reason for drop-out of long-term therapy. 11 In addition to somnolence and headache, self-felt anger is often a problem for patients who initially take levetiracetam. 12 The risk of adverse effects has to be carefully balanced against the risk of seizures. Lower dosages of AEDs than are typically recommended may reduce the rate of adverse effects. Given this emerging data, the objective of this study was to provide information about the efficacies of LEV and VPA as initial low-dose monotherapies in typical BECTS.
Methods
This was a retrospective, uncontrolled, case-comparison cohort study of preselected subjects from the Epilepsy Clinic of the Department of Neurology, West China Hospital of Sichuan University between June 2010 and January 2012. The inclusion criteria were as follows: (1) newly diagnosed BECTS according to the current clinical and electroencephalographic criteria adopted by the ILAE 13 ; (2) the presence of the specific EEG characteristics at any time before or during the study and an age-typical EEG background rhythm; (3) typical seizures that were hemifacial, characterized by hemifacial clonic manifestations that were sometimes preceded by unilateral paresthesia involving the tongue, lips, gums and cheek and jerks that were often associated with lateral tonic deviations of the mouth involving the lips and tongue and resulted in drooling due to sialorrhea with or without secondary generalization; (4) no other neurologic, psychiatric, or somatic disorders; (5) no evidence of structural brain damage based on magnetic resonance imaging; (6) normal neurological and mental status; (7) at least two seizures within 6 months prior to the initiation of treatment; and (8) regular visits to our clinic for at least 18 months. The exclusion criteria were as follows: (1) previous treatment with AEDs prior to visiting our clinic or refusal to receive drug treatment; (2) incomplete statistical information; (3) failure to return for follow-up; and (4) cessation of drug treatment without permission. The local research ethics committee approved this study, and written informed consent was obtained from the parents or caregivers. Ultimately, 56 subjects (36 male, 20 female) with typical BECTS maintained VPA or LEV monotherapy for at least 18 months. The ages of seizure onset ranged from 4.0 to 13.5 years, and the mean peak frequency occurred at 8.1 AE 1.9 years.
LEV was administered as the first drug in 33 patients (19 boys, 14 girls), and VPA was administered first in 23 patients (18 boys, 5 girls). Thus, the 56 patients were divided into the following two groups: the LEV therapy group, and the VPA therapy group (see Table 1 for details). The LEV therapy group began with LEV at 250 mg per night, and the dose was gradually escalated. The patients in the VPA therapy group began with VPA at 250 mg per night, and the dose was gradually escalated. All patients were carefully followed at 6, 12, and 18 months after the beginning of the therapy. All cases received 24-h video EEG at diagnosis and overnight video EEG during the follow-up. The parents or caregivers routinely recorded the date, number, and type of the seizures, the maximum durations of the clusters (which were counted as one seizure) and adverse events in an epilepsy diary. All of the parents or caregivers accompanied their children during sleep to monitor any seizure activity after the initiation of therapy. At each clinic visit, we assessed the seizure numbers and possible adverse effects that were related to AED treatment. The evaluations of the patients began at the end of the AED titration. The efficacy of the treatment in each therapy group was assessed by the number of ictal seizure events. Physical and neurological examinations, laboratory assessments, and electrocardiography were performed; vital signs were recorded; and height and weight were monitored at baseline and at each of the follow-ups (i.e., 6-, 12-and 18-month evaluations). The body mass indices (BMIs) were calculated at each of these points by dividing the weight in kilograms by the square of the height in meters. National growth chart findings based on data collected in a survey of local children were used to obtain the mean body weights for height. 14 The BMI categories were defined as underweight (BMI < 18.5), appropriate (BMI 18.8-22.9), potentially overweight (BMI 23.0-25.0) and overweight (BMI > 25.0). Patients with BMI increases exceeding 1.5 per 6 months were categorized as exhibiting weight gain. Physical and neurological abnormalities detected during treatment were recorded as adverse events as were any worsening of the condition and requirements for medication. Detailed records of the adverse events were documented.
The primary outcome measures were complete seizure freedom, EEG normalization and the favorable side effect profile of each drug ( Figs. 1 and 2 ).
Statistical analyses
Statistical analyses were performed using commercially available SPSS 19.0. The differences between the treatment groups were assessed using the two-tailed Fisher's exact test. The significance level was set at p < 0.05.
Results
All 56 children maintained the LEV or VPA monotherapy with good compliance during the 18 months of therapy. Detailed results of each patient in the LEV group in terms of seizure control and EEG outcomes at 6, 12 and 18 months are presented in Table 2 , and the corresponding information for the VPA group is presented in Table 3 . Abbreviation: VPA, valproic acid; LEV, levetiratacem; BMI, body max index; CT, centrotemporal; CPT, centroparietotemporal; CFT, centrofrontotemporal; SPS, simple partial seizure; CPS, complex partial seizure; CPS-GTCS, complex partial seizure secondary with generalized tonic-clonic seizure. 
Assessment of seizure and EEG outcomes at 6 months
In the LEV group, 19 (57.6%) of the 33 children were seizurefree, and 14 (42.4%) experienced at least one episode. Nine (27.3%) children exhibited normal EEGs, and 14 (72.7%) exhibited sporadic rolandic epileptiform discharges. In the VPA group, 14 (60.9%) of the 23 children were seizure-free, and 9 (39.1%) reported at least one episode. The EEGs were normal in 12 (52.2%) children, and sporadic rolandic epileptiform discharges persisted in 11 (47.8%) patients. No significant differences were detected in the efficacies of two drugs (Table 4) .
Assessment of seizure and EEG outcomes at 12 months
In the LEV group, 27 children (81.8%) were completely seizurefree. Six children (18.2%) reported at least one seizure. Eighteen children (55.5%) exhibited normal EEG results, and 15 (54.5%) patients exhibited abnormal EEGs. In the VPA group, 17 children (73.9%) were completely seizure-free, and 6 children (26.1%) exhibited at least one seizure. Eighteen children (78.3%) exhibited normal EEGs, and 5 (21.7%) patients had abnormal EEGs. The difference between the EEG normalizations of the groups was statistically significant (p = 0.026; Table 5 ).
Assessment of seizure and EEG outcomes at 18 months
In the LEV group, all of the children were seizure free. Twentyfour children achieved normal EEGs (72.7%), and 9 (27.3%) exhibited continued EEG abnormality. Of these nine patients, seven exhibited rolandic discharges that were unchanged relative to their prior two EEG follow-ups, and the other two patients exhibited sporadic rolandic spikes (i.e., no spikes were detected during the routine EEG monitoring, but infrequent spikes were detected in the overnight EEGs). In the VPA group, all of the children were seizure-free, and only one child exhibited an abnormal EEG. The EEG normalization outcomes of the VPA group were superior to those of the LEV group (p = 0.036; Table 6 ).
The patients who exhibited normalized EEGs were younger (8.4 AE 2.0 years) than those with persistently abnormal EEGs (8.9 AE 1.6 years). However, this difference was not statistically significant (p = 0.45).
Titrations and safeties of the treatments
No adverse hematological, biochemical, or behavioral side effects were reported in any children. Additionally, none of the children exhibited worsening of their seizures.
In the LEV group, only one child (patient 17) received an increase in dosage during the first 6 months due to frequent seizures, which decreased at the 12-month follow-up. The LEV dosages ranged from 15.2 to 37.9 mg/kg/daily (mean 22.7 AE 4.7 mg/kg/daily). Six children (18.2%) reported episodes of dizziness and transient somnolence in the first few days following the initiation of LEV treatment, two children (5.4%) reported irritability, and one child (2.7%) exhibited mild hair loss. These reported adverse effects were either mild or transient and thus did not lead to withdrawal from drug treatment. The physical and neurological examinations and psychiatric and mental statuses of all patients were unremarkable.
In the VPA group, all of the children maintained the low-dose treatment with VPA (the doses ranged from 9.3 to 27.0 mg/kg/ daily, and the mean dose was 18.6 AE 5.7 mg/kg/daily). Four children (17.4%) reported mild drowsiness, and one child (4.3%) exhibited mild weight gain (BMI increase of 2 at the end of follow-up). None of these patients discontinued VPA treatment because their daily life activities were not significantly affected.
Discussion
Whether BECTS should be treated with antiepileptic medications remains controversial due to the mild nature and optimistic outcomes of this condition. 2, 15 Of 110 recommendations in the literature that were identified in a review, two-thirds generally favored treatment with AEDs, and one-third did not recommend treatment. 2 For those children with recurring seizures and psychiatric comorbidities, effective and safe monotherapy is the top priority. 16, 17 A previous study reported that all children achieved the remission of seizures following the administration of low-dose VPA in a series of 43 BECTS patients. 18 Our study examined the treatment of BECTS with low-dose, long-term LEV, or VPA monotherapy (average dose of 22.7 and 18.6 mg/kg/day, respectively). These drugs were equally effective in controlling seizures in the children with typical BECTS; the seizure-free rates Abbreviation: M, male; F, female; R, right; L, left; Bi, bilateral; CT, centrotemporal; CPT, centroparietotemporal; CFT, centrofrontotemporal; diffusion, occasional sharp waves diffusing to one or both hemisphere. were not significantly different between two groups at the 6-, 12-, or 18-month follow-ups. A greater number of children who received the VPA treatment achieved EEG normalization than did those who received the LEV treatment at 12 (78.3% vs. 45.5%, respectively) and 18 months (95.7% vs. 72.7%, respectively). Levetiracetam (LEV) is a unique antiepileptic medication that has multiple mechanisms of action, which differentiates it from conventional AEDs. 16, 17 The favorable safety profile, minimal drug interactions, high bioavailability, and linear pharmacokinetics of LEV make it a nearly ideal agent for children. The clearance of LEV is 30-40% faster in children than in adults; hence, children can tolerate high oral doses of LEV. 19 In the present study, all of the children responded well to low-dose LEV (mean dose: 22.7 AE 4.7; maximum dose: 37 mg mg/kg/day). As reported in previous studies, 20, 21 somnolence (18.4%) and irritability (5.4%) were the most common side effects in the LEV group. All of these side effects were confirmed to be transient, occurred only during the initial phase (<4 weeks) of LEV treatment, and did not result in any discontinuation of treatment. Hair loss has previously been reported in adult patients taking LEV, 22 is typically mild, and was observed in one child in this cohort. Our present results confirm that LEV is an effective and safe medication for children with BECTS. 21 The 2013 updated ILAE guidelines 10 reported that there is level C evidence for the use of valproic acid (VPA) as the initial monotherapy for BECTS. VPA is also listed by European experts as ''the treatment of choice'' for BECTS. 23 Notably, VPA can often cause important side effects, such as weight gain, hyperinsulinism, menstrual irregularities, polycystic ovary syndrome and temporary alopecia, that negatively impact the quality of life, particularly for female adolescents. 24 Weight gain is the most common reason for VPA withdrawal in children with epilepsy. 25 In contrast, only one of the 23 children (4.3%) in the VPA group exhibited mild weight gain, and weight gain did not influence compliance in the current study. Our results are inconsistent with those of recent study that found that 8 of 15 children (10 girls, 5 boys) taking sodium valproate at a dosage of 17.4 mg/kg/day exhibited weight gain during the follow-up. These effects occurred only in the girls (i.e., 8 girls and 0 boys), were transient, and did not result in the discontinuation of VPA treatment largely due to the application of behavioral therapy. 26 Weight gain in female patients taking VPA is partially associated with metabolic syndrome. 27 The low incidence of weight gain in the present study might have resulted from the small number of girls (5 girls, 18 boys) who underwent VPA treatment in this study. Notably, specific programs for weight management, such as behavioral therapy, were not applied in this study. The parents and caregivers were encouraged to guide the children toward developing healthy lifestyles that included fewer sedentary activities, regular physical activity, and healthy eating habits throughout the follow-up. Our results suggest that low-dose VPA is sufficiently effective to control seizures in BECTS patients and provide reassurance that weight gain will not persist with lowdose VPA even in the absence of weight management. Notably, low-dose VPA exhibited greater efficacy than low-dose LEV in improving the electrophysiological abnormalities of the children with BECTS. In contrast to the LEV group, none of the patients in the VPA group exhibited diffusion on EEG. However, only one of the five patients who exhibited diffusion in the LEV group also exhibited persistent sporadic EEG spikes at the end of the follow-up, and this finding has little effect on the interpretation of our results. Prior studies have shown that VPA can reduce abnormal epileptiform activity in childhood epilepsy and pediatric psychosis. 28, 29 Whether epileptiform discharges that are not part of a seizure require treatment remains controversial. 30 However, recent clinical studies with large samples have suggested that frequent interictal epileptiform discharges can impair cognitive performance in children. 31, 32 Interictal discharges can cause transitory cognitive impairment, and the type of deficit depends on the cortex from which the spikes arise. Rolandic spikes over the centrotemporal regions of both left and right hemispheres can cause receptive language dysfunction, verbal learning deficits, speech sound disorder, fine motor deficits and reduced performance IQ. 33 Damage to the short-term memory subserved by the perisylvian areas in which the rolandic spikes are located poses a high risk for educational problems for children with BECTS. 34, 35 GRIN2A is a genetic determinant of rolandic spikes and causes cerebral maturation disorder that predisposes patients to epilepsy. Furthermore, the accentuation of EEG discharges can exacerbate cognitive disorders and language dysfunctions. 36 Attention deficit hyperactivity disorder is the most common comorbidity of BECTS. 37 Both longitudinal observations and genetic discoveries suggest that attention impairments appear to be correlated with EEG activity in BECTS and not specifically with seizure activity. 3, 38, 39 The present study was not designed to determine whether the interictal spikes should be treated. Nevertheless, because seizures are often infrequent in these patients, the reduction of interictal epileptic activity might be of clinical importance in terms of the measurement of the success of AED treatments. Our experience revealed that low-dose VPA might be capable of simultaneously halting seizures and normalizing EEG abnormalities and thus reducing the risk of cognitive impairment. Given the small sample size and retrospective and nonrandomized design of this study, we cannot make definitive conclusions. One important limitation of this study is that serum drug level data are more reliable than weight-based dosages, particularly for VPA, but these data were not available. The clearances of VPA and LEV are also higher in younger children. Another limitation is that the interictal spikes were not quantified at baseline. It is possible that the VPA group exhibited frequent spikes at baseline prior to treatment and thus exhibited a higher rate of EEG normalization. Moreover, the potential neuropsychological correlates of the electrophysiological improvements were not investigated; longitudinal studies would be beneficial for the examination of such issues.
Valproic acid is a classic and powerful antiepileptic agent and has frequently been recommended with the caveat of potential metabolic and weight issues. 40 However, in our study, no children withdrew from VPA treatment throughout the 18-month followup. Low dosages may be the solution to excessive weight issues related to the long-term use of VPA. Additionally, low-dose VPA seemed to exhibit greater efficacy than did LEV in the normalization of EEG abnormalities in BECTS. Our preliminary results seem to favor VPA or LEV as potential initial drugs for children with typical BECTS. Despite its significant drug interactions, VPA remains the mainstay of initial monotherapy for children with epilepsy. 41 For children with typical BECTS, low-dose treatment may be sufficient.
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